Patents by Inventor Patrice Douillard

Patrice Douillard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADENO-ASSOCIATED VIRUS VECTORS BASED GENE THERAPY FOR HEREDITARY ANGIOEDEMA
    Publication number: 20230043051
    Abstract: The present disclosure provides, among other things, a recombinant adeno-associated virus (rAAV) vector comprising an AAV8 capsid and a codon-optimized SERPING1 sequence encoding a human C1-esterase inhibitor. The disclosure also provides a method of treating a subject having Hereditary angioedema (HAE), comprising administering to the subject in need thereof a recombinant adeno-associated virus (rAAV) vector comprising an AAV8 capsid, and codon-optimized SERPING1 sequences encoding a human C1-esterase inhibitor.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 9, 2023
    Inventors: Matthias Klugmann, Franziska Horling, Johannes Lengler, Patrice Douillard, Friedrich Scheiflinger, Hanspeter Rottensteiner, Bagirath Gangadharan
  • Anti-MIF immunohistochemistry
    Patent number: 11402388
    Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, in tissues. A detection method is provided which uses immunohistochemistry and wherein specific anti-oxMIF antibodies are used.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: August 2, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Michael Thiele, Randolf Kerschbaumer, Dirk Voelkel, Patrice Douillard, Friedrich Scheiflinger, Alexander Schinagl
  • DETECTION OF CHO-MIF CONTAMINATIONS
    Publication number: 20200207840
    Abstract: The invention concerns a detection method to enable the detection of complexes formed between antibodies and antigen which is endogenous to the production cell line, e.g. CHO MIF in a final product.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 2, 2020
    Inventors: Dirk Voelkel, Patrice Douillard, Gerhard Antoine, Randolf Kerschbaumer
  • Detection of CHO-MIF contaminations
    Patent number: 10626166
    Abstract: The invention concerns a detection method to enable the detection of complexes formed between antibodies and antigen which is endogenous to the production cell line, e.g. CHO MIF in a final product.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: April 21, 2020
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Dirk Voelkel, Patrice Douillard, Gerhard Antoine, Randolf Kerschbaumer
  • Anti-MIF immunohistochemistry
    Patent number: 10613100
    Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, and of anti-oxMIF antibodies in tissues. A detection method is provided which uses immunohistochemistry or immunofluorescence and wherein specific anti-oxMIF antibodies and specific idiotypic monoclonal rabbit antibodies are used.
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: April 7, 2020
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Alexander Schinagl, Michael Thiele, Patrice Douillard, Gerhard Antoine, Randolf Kerschbaumer
  • DETECTION OF CHO-MIF CONTAMINATIONS
    Publication number: 20180215807
    Abstract: The invention concerns a detection method to enable the detection of complexes formed between antibodies and antigen which is endogenous to the production cell line, e.g. CHO MIF in a final product.
    Type: Application
    Filed: August 21, 2015
    Publication date: August 2, 2018
    Inventors: Dirk Voelkel, Patrice Douillard, Gerhard Antoine, Randolf Kerschbaumer
  • ANTI-MIF ANTIBODIES IN THE TREATMENT OF CANCERS CONTAINING MUTANT TP53 AND/OR MUTANT RAS
    Publication number: 20180155419
    Abstract: The present invention pertains to anti-MIF antibodies, preferably in combination with cancer therapeutics, i.e. chemotherapeutic agents, in the treatment of cancers containing mutant TP53 and/or mutant RAS.
    Type: Application
    Filed: May 18, 2016
    Publication date: June 7, 2018
    Inventors: Patrice Douillard, Randolf Kerschbaumer, Michael Thiele, Salim Yazji
  • OxMIF as a diagnostic marker
    Patent number: 9958456
    Abstract: The present invention pertains to the recognition that a specific oxMIF form of MIF is useful as a diagnostic marker in (MIF-related) diseases, in particular for example monitoring of disease progression. The present invention also pertains to the respective use of a diagnostic kit and a respective diagnostic assay and pertains to advantageous respective antibodies.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: May 1, 2018
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Michael Thiele, Randolf J. Kerschbaumer, Dirk Voelkel, Patrice Douillard, Friedrich Scheiflinger
  • ANTI-MIF IMMUNOHISTOCHEMISTRY
    Publication number: 20160334414
    Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, and of anti-oxMIF antibodies in tissues. A detection method is provided which uses immunohistochemistry or immunofluorescence and wherein specific anti-oxMIF antibodies and specific idiotypic monoclonal rabbit antibodies are used.
    Type: Application
    Filed: January 2, 2015
    Publication date: November 17, 2016
    Inventors: Alexander Schinagl, Michael Thiele, Patrice Douillard, Gerhard Antoine, Randolf Kerschbaumer
  • ANTI-MIF IMMUNOHISTOCHEMISTRY
    Publication number: 20150160235
    Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, in tissues. A detection method is provided which uses immunohistochemistry and wherein specific anfi-oxMIF antibodies are used.
    Type: Application
    Filed: July 9, 2013
    Publication date: June 11, 2015
    Inventors: Michael Thiele, Randolf Kerschbaumer, Dirk Voelkel, Patrice Douillard, Friedrich Scheiflinger, Alexander Schinagl
  • OXMIF AS A DIAGNOSTIC MARKER
    Publication number: 20140248638
    Abstract: The present invention pertains to the recognition that a specific oxMIF form of MIF is useful as a diagnostic marker in (MIF-related) diseases, in particular for example monitoring of disease progression. The present invention also pertains to the respective use of a diagnostic kit and a respective diagnostic assay and pertains to advantageous respective antibodies.
    Type: Application
    Filed: October 4, 2012
    Publication date: September 4, 2014
    Inventors: Michael Thiele, Randolf J. Kerschbaumer, Dirk Voelkel, Patrice Douillard, Friedrich Scheiflinger